Microbot Medical Inc. Receives FDA 510(k) Clearance for LIBERTY® Endovascular Robotic System, Prepares for Q4 Commercial Launch

Reuters
2025/10/16
<a href="https://laohu8.com/S/MBOT">Microbot Medical Inc</a>. Receives FDA 510(k) Clearance for LIBERTY® Endovascular Robotic System, Prepares for Q4 Commercial Launch

Microbot Medical Inc. has announced that it recently received FDA 510(k) clearance for its LIBERTY® Endovascular Robotic System. This regulatory approval allows the company to move forward with its commercial launch plans, including exhibiting the system at the upcoming Symposium on Clinical Interventional Oncology. The clearance was granted solely to Microbot Medical Inc., and the company has also completed recruitment of its commercial leadership team in preparation for a limited market launch later this quarter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Microbot Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9546625-en) on October 16, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10